Orion Oyj Dirección

Dirección controles de criterios 3/4

El CEO de Orion Oyj es Liisa Hurme , nombrado en Jan 2019, tiene una permanencia de 5.83 años. compensación anual total es €819.50K, compuesta por 81.6% salario y 18.4% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.023% de las acciones de la empresa, por valor de €1.42M. La antigüedad media del equipo directivo y de la junta directiva es de 2 años y 4.5 años, respectivamente.

Información clave

Liisa Hurme

Chief Executive Officer (CEO)

€819.5k

Compensación total

Porcentaje del salario del CEO	81.6%
Permanencia del CEO	5.8yrs
Participación del CEO	0.02%
Permanencia media de la dirección	2yrs
Promedio de permanencia en la Junta Directiva	4.5yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Liisa Hurme en comparación con los beneficios de Orion Oyj?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	€332m
Jun 30 2024	n/a	n/a	€232m
Mar 31 2024	n/a	n/a	€217m
Dec 31 2023	€820k	€668k	€217m
Sep 30 2023	n/a	n/a	€173m
Jun 30 2023	n/a	n/a	€306m
Mar 31 2023	n/a	n/a	€336m
Dec 31 2022	€106k	€106k	€350m

Compensación vs. Mercado: La compensación total de Liisa($USD862.72K) está por debajo de la media de empresas de tamaño similar en el mercado UK ($USD3.25M).

Compensación vs. Ingresos: La compensación de Liisa ha aumentado más de un 20% en el último año.

CEO

Liisa Hurme (57 yo)

5.8yrs

Permanencia

€819,500

Compensación

Dr. Liisa Hurme, PhD (Biochemistry), has been President , Chief Executive Officer and Chairman of Managemenbt board at Orion Oyj since Novemnber 01, 2022. Dr. Hurme served as Senior Vice President, Global...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Liisa Hurme	President	5.8yrs	€819.50k	0.023% € 1.4m
Rene Lindell	Chief Financial Officer & Member of Group Executive Management Board	less than a year	sin datos	sin datos
Olli Huotari	Senior VP of Corporate Functions	22.1yrs	sin datos	0.060% € 3.7m
Satu Ahomäki	Senior VP of Generics and Consumer Health Business Division & Member of the Exe. Mgmt. Board	16.8yrs	sin datos	0.025% € 1.5m
Outi Vaarala	Sr. VP of Innovative Medicines	4.4yrs	sin datos	0.010% € 636.6k
Juhani Kankaanpaa	Senior VP of Global Operations & Member of Executive Management Board	2yrs	sin datos	0.0036% € 222.2k
Niclas Lindstedt	Senior VP of Animal Health Business Division & Member of the Exe. Mgmt. Board	1.8yrs	sin datos	0.0031% € 190.4k
Hao Pan	Senior VP of the Branded Products Business Division & Member of the Exe. Mgmt. Board	1.8yrs	sin datos	0.010% € 647.8k
Julia Macharey	Senior Vice President of People & Culture and Member of Management Board	less than a year	sin datos	sin datos
Tuukka Hirvonen	Investor Relations & Financial Communications Officer	no data	sin datos	sin datos
Terhi Ormio	Vice President of Communications	15.6yrs	sin datos	sin datos
Virve Laitinen	Sr. VP of Corporate Strategy and Program Mgmt. Grp. Level Function & Head of CSPMO	less than a year	sin datos	0.023% € 1.4m

2.0yrs

Permanencia media

55yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 0M2N se considera experimentado (2 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Mikael Silvennoinen	Independent Director	10.7yrs	€123.40k	0.0069% € 431.2k
Veli-Matti Mattila	Independent Chairman	3.7yrs	€61.40k	0.0066% € 410.7k
Henrik Stenqvist	Director	less than a year	sin datos	sin datos
Kari Aho	Independent Director	4.5yrs	€61.40k	0.062% € 3.9m
Ari Lehtoranta	Independent Director	7.7yrs	€72.40k	0.0036% € 225.9k
Maziar Doustdar	Independent Director	2.7yrs	€60.80k	0.0011% € 67.2k
Eija Ronkainen	Independent Director	8.7yrs	€61.40k	0.41% € 25.5m
Hilpi Rautelin	Independent Vice Chairman of the Board	7.7yrs	€81.10k	0.0073% € 452.4k
Karen Soerensen	Independent Director	2.7yrs	€66.80k	0.0011% € 67.2k

4.5yrs

Permanencia media

62yo

Promedio de edad

Junta con experiencia: La junta directiva de 0M2N se considera experimentada (4.5 años de antigüedad promedio).

Orion Oyj Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Orion Oyj, Annual General Meeting, Apr 03, 2025

Orion Corporation Announces Change in Orion Group Executive Management Board as of 31 May 2025

Orion Corporation Announces Appointments to Nomination Committee

Orion Corporation Announces Change in Executive Management Board, Effect as of 1 April 2024

Orion Corporation Announces Board and Committee Appointment

Orion Oyj Announces Retirement of Mikael Silvennoinen as Board Member

Recent updates

Orion Oyj Updates Earnings Guidance for the Full Year 2024

Orion Corporation Decides to Terminate the ODM-111 Development Program

Orion Oyj, Annual General Meeting, Apr 03, 2025

Orion Oyj to Report First Half, 2025 Results on Jul 18, 2025

Orion Announces Phase III Aranote Trial of Darolutamide in Combination with Androgen Deprivation Therapy in Men with Metastatic Hormone-Sensitive Prostate Cancer Meets Primary Endpoint

Orion Oyj Revises Earnings Guidance for the Year 2024

Orion Corporation Announces Change in Orion Group Executive Management Board as of 31 May 2025

Orion Corporation Announces Appointments to Nomination Committee

Orion Corporation Announces Change in Executive Management Board, Effect as of 1 April 2024

Orion Corporation Announces Board and Committee Appointment

Orion Oyj Announces Retirement of Mikael Silvennoinen as Board Member

Orion Oyj Announces CFO Changes

Orion Corporation Announces Phase 3 Clinical Trials with ODM-208 (MK-5684) posted to ClinicalTrials.gov Database

Orion Corporation Receives Fda Approval for Bonqat (Pregabalin Oral Solution)

Orion Group Appoints Julia Macharey as Senior Vice President, People & Cultur

Orion Oyj to Report Q3, 2024 Results on Oct 29, 2024

Orion Oyj Announces Resignation of Jari Karlson as Chief Financial Officer

Orion Oyj Provides Earnings Guidance for the Year 2023

Orion Oyj Announces Positive CHMP Opinion for Darolutamide in Combination with Docetaxel for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer

Orion Group Provides Earnings Guidance for the Full Year 2022

Orion Group Appoints Liisa Hurme as CEO, Effective 1 January 2023

Orion Oyj Announces Executive Changes

Orion Announces Approval of Additional Indication of Darolutamide in Combination with Docetaxel for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer (Mhspc) from U.S. FDA

Orion Oyj to Report Nine Months, 2023 Results on Oct 26, 2023

Orion Oyj to Report Q1, 2023 Results on Apr 27, 2023

Orion Oyj Revises Earnings Guidance for the Full Year 2022

Orion Oyj to Report Q2, 2022 Results on Jul 15, 2022

Orion Oyj (HLSE : ORNBV) acquired V.M.D. n.v./s.a. from Inovet Bv for €130 million.

Orion Oyj (HLSE : ORNBV) acquired V.M.D. n.v./s.a.from Inovet Bv for €130 million.

Orion Oyj Announces Executive Changes

Orion Oyj Appoints Liisa Hurme as President and the Chair of the Executive Management Board, as of 1 November 2022

Orion’S Collaboration Partner Bayer Submits Applications in the U.S. and Eu for Additional Indication of Darolutamide

Orion Corporation Announces Results from an Ongoing Phase I/II CYPIDES Trial of ODM-208 Present at ASCO-GU

Orion Oyj Provides Earnings Outlook for the Year 2022

Orion Announces Arasens Trial with Darolutamide in Combination with Docetaxel and Androgen Deprivation Therapy Meets Primary Endpoint of Significantly Increasing Overall Survival in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Orion Oyj Provides Earnings Guidance for the Year 2021

Orion Oyj Recalls Multivita Forte Dietary Supplement from Consumers

Orion Animal Health’s Tessie® (tasipimidine) Receives Positive CVMP Opinion

Orion Corporation’s Clinical Trial Shows Significant Improvement for Chronic Pain Patients Using Virtual Reality Therapy

Orion Animal Health’s Bonqat® (Pregabalin) Receives Positive CVMP Opinion

Orion Oyj Provides Earnings Guidance for the Year 2021

Orion Corporation and Bayer Expand Development Program for Darolutamide in Prostate Cancer

Tenax Therapeutics, Inc. Enters into Amendment to License Agreement with Orion Corporation

Orion Is Planning to Renew Its R&D Strategy and Organisation

Orion Oyj to Report First Half, 2021 Results on Jul 19, 2021

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad